Previous 10 | Next 10 |
CHESTERBROOK, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has resubmitted its New Drug...
CHESTERBROOK, Pa., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and C...
CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a proof-of-concept...
Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines ...
Trevena ( TRVN ) is a biopharmaceutical company focused on developing targets and treatments for diseases affecting the central nervous system and pain relief. The main drug the company is developing is called oliceridine a mu-opioid receptor for the management of moderate-to-severe acute pain...
Trevena (NASDAQ: TRVN ) announces publication of results from two Phase 1 pharmacokinetic (PK) studies of IV oliceridine. More news on: Trevena, Inc., Healthcare stocks news, Read more ...
Trevena (NASDAQ: TRVN ) announces results from the Phase 3 open-label safety study (ATHENA) for IV oliceridine in The Journal of Pain Research . More news on: Trevena, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Safety and tolerability demonstrated in diverse patient populations and surgeries CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centra...
No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel ...
CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vi...
News, Short Squeeze, Breakout and More Instantly...
2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. ("Trevena" or the "Company") (NASDAQ:TRVN), a biopharmaceutical company focus...